Eight-week mindfulness-based stress reduction reduced fatigue, anxiety, and depression in non-small cell lung cancer patients.
Mindfulness training helped lung cancer patients feel less tired and anxious after surgery
This randomized controlled trial evaluated an eight-week mindfulness-based stress reduction program in 80 non-small cell lung cancer patient…
An eight-week mindfulness program helped lung cancer patients feel less tired and anxious during recovery from surgery and chemotherapy.
mHealth interventions improve medication adherence and self-efficacy in cancer patients, meta-analysis finds
Mobile apps and texts help cancer patients stick to their medication better
A systematic review and meta-analysis of 17 RCTs involving 1309 cancer patients found mobile health interventions significantly improved med…
Phone apps and text reminders make cancer patients about three and a half times more likely to take their medicine on time.
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals. The ev…
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
Pharmacist-led interventions reduce adverse reactions and improve outcomes in cancer patients
Pharmacist care reduces side effects and improves quality of life for cancer patients
This systematic review and meta-analysis of randomized controlled trials and non-randomized intervention studies evaluated pharmacist-led in…
Adding a pharmacist to cancer care teams significantly reduces nausea and vomiting while improving pain control and quality of life for pati…
Tumor budding associates with adverse clinicopathological features and reduced overall survival in cervical and endometrial cancer.
Tumor Budding Linked to Worse Outcomes in Cervical and Endometrial Cancer
This Bayesian meta-analysis of 18 observational cohort studies involving 3320 patients with cervical or endometrial cancer evaluated the pro…
Small clusters of cells breaking away from cervical and endometrial tumors signal more aggressive disease and worse survival outcomes.
Meta-analysis finds increased bleeding with antithrombotic therapy during breast biopsy, but clinically relevant events are rare
Continuing blood thinners during breast biopsy increases minor bleeding but rarely serious problems
A systematic review and meta-analysis of 8 studies including 11,524 patients undergoing image-guided breast biopsy found that continuing ant…
Continuing blood thinners during a breast biopsy slightly increases minor bleeding but rarely causes serious problems like heart attacks or …
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12
Ponatinib doses show early signs in resistant chronic myeloid leukemia patients
This Phase 2 study evaluated ponatinib in 283 participants with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior tyrosine-…
Ponatinib at three daily doses showed early signs of helping resistant chronic myeloid leukemia patients reach a key molecular response goal…
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Encorafenib plus binimetinib maintains quality of life in BRAF V600E-mutated thyroid cancer
Can new drugs help advanced thyroid cancer patients keep their daily life stable?
An uncontrolled phase 2 trial of 22 patients with BRAF V600E-mutated thyroid cancer found encorafenib plus binimetinib was associated with g…
A new drug combination helped advanced thyroid cancer patients maintain daily life stability without worsening their quality of life during …
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier.
Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.…
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Oral paclitaxel shows similar efficacy to IV paclitaxel in phase II metastatic breast cancer trial
Can an oral pill match the power of standard IV chemo for advanced breast cancer?
A phase II randomized trial of 72 patients with HER2-negative recurrent or metastatic breast cancer found oral paclitaxel (DHP107) had an ob…
An oral breast cancer pill matched IV chemo in stopping tumor growth while sparing patients from nerve damage and hair loss.